SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-07-11			5-day change	1st Jan Change
11.02 ^CNY	+0.36%		+0.27%	-7.71%

Jul. 01	Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	MT
Jun. 05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT

China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection

Published on 05/15/2024 at 06:28, updated on 05/15/2024 at 06:30

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	Jul. 01	MT
Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	Jun. 05	MT
Shyndec Pharma Gets Registration Certificate for Hypertension Drug	Jun. 05	MT
Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	May. 29	MT
Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	May. 14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 28	CI
Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	Apr. 16	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 27	CI
Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug	Mar. 18	MT
Shyndec Pharmaceutical's Unit Gets Registration Certificate for Methylprednisolone Tablets	Mar. 17	MT
Shyndec Pharmaceutical Obtains Registration Certificates for Antiviral, Anticoagulant Drugs	Mar. 10	MT
Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation	Mar. 03	MT
Shyndec Pharma's Units Get Three Drug Registration Certificates	Jan. 22	MT
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection	Jan. 20	MT
Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation	Jan. 20	MT
Shyndec Pharma Gets China Pharmaceutical Ingredient Approval for Anaesthesia Supplementary Drug	Jan. 08	MT
Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	Jan. 03	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(SHSE:600420) added to Shanghai Stock Exchange Health Care Sector Index	Dec. 17	CI
Shanghai Shyndec Pharmaceutical Unit Gets China Nod for Antibiotic Ingredient	Dec. 17	MT
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets	Dec. 12	MT
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials	Dec. 05	MT
Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops	Dec. 03	MT
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	Nov. 27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	Nov. 26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

Aug. 29 - Q2 2025 Earnings Release

More about the company